The Top 10 Companies Reshaping Continuous Bioprocessing

The global Continuous Bioprocessing Market is poised for substantial growth, projected to reach $1.32 billion by 2031, with a robust Compound Annual Growth Rate (CAGR) of 19.6% during the forecast period. Continuous bioprocessing, characterized by its single-unit operation in biomanufacturing, offers a streamlined approach to processing raw materials, resulting in enhanced manufacturing cost efficiency, increased output capacity, and intensified production of biopharmaceuticals. This innovative approach is particularly valuable in the commercial manufacturing of monoclonal antibodies (mAb), cell & gene therapies, vaccines, and recombinant proteins.